Large company small molecule share of Phase I clinical trial starts
Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs.
Unit Percent Industry Pharmaceuticals
The chart
Over time
Global over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
Every record
All records
4 records · 1 region · 2022–2025
| Period | Value | Source | Type |
|---|---|---|---|
| Global 4 records | |||
| 2025 | 66% | IQVIA · 31 Dec 2025 | actual |
| 2025 | 66% | IQVIA · 31 Dec 2025 | actual |
| 2022 | 61% | IQVIA · 31 Dec 2022 | actual |
| 2022 | 61% | IQVIA · 31 Dec 2022 | actual |
Primary documents
Sources
2 documents. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Global R&D Trends 2026 | IQVIA | — | 2 |
| Global R&D Trends 2026 | IQVIA | — | 2 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Large company small molecule share of Phase I clinical trial starts. Retrieved from https://statorigin.org/indicators/large-company-small-molecule-share-of-phase-i-clinical-trial-starts